Data on recombinant C1 esterase inhibitor as treatment for HAE to be presented at 2025 ACAAI Annual Scientific Meeting

[Recombinant C1 esterase inhibitor is also often referred to by its brand name, Ruconest]

Five abstracts on recombinant C1 esterase inhibitor, used as a treatment for HAE, will be presented by the pharmaceutical company Astria Therapeutics at the American College of Allergy, Asthma and Immunology (ACAAI) 2025 Annual Scientific Meeting in Orlando, USA, from 6-10 November 2025.

These posters will present positive new clinical, economic, and comparative data for recombinant C1 esterase inhibitor and its role in on-demand HAE treatment.

Anurag Relan, Chief Medical Officer of Pharming, commented: “We are proud that our scientific contributions in hereditary angioedema (HAE) have been recognized with a significant number of abstract acceptances at this year’s ACAAI. The work underscores the rigor of our research and our commitment to advancing patient care. We look forward to the new data being presented to the medical community during the meeting in November.”

(Source: Pharming)